MSM have among the highest HIV-1 incidence in sub-Saharan Africa, but targeted interventions for HIV-1 testing of MSM are mostly lacking [@R1; @R2; @R3]. When HIV-1 is acquired, patients may frequently seek urgent healthcare for symptoms, including fever or unconfirmed 'malaria' [@R4; @R5; @R6], and become extremely infectious during a short period of 3--4 weeks (acute HIV infection; AHI) and highly contagious during the first 6 months (early HIV-1 infection) [@R7; @R8]. However, diagnosing acute and early HIV-1 infection (AEHI) remains challenging in resource-limited settings, in part due to a lack of low-cost, point-of-care tests for nucleic acid detection [@R9]. In Malawi, the UNC Malawi Risk Screening Score (UMRSS) combining discrete clinical and behavioral characteristics has been developed to identify AHI among sexually transmitted diseases (STDs) clinic patients [@R10]. In this study, STD patients who were HIV-1 negative or had discordant rapid HIV tests received a score of 1 for fever, body ache, and more than one partner; 2 for diarrhea and genital ulcer disease (GUD); and 4 for discordant rapid tests. Using this algorithm, Powers *et al.*[@R10] could identify 95% of the AHI cases identified by targeted testing of only patients with a score of 2 or greater (40% of the population studied). As MSM frequently present with an STD, we wanted to validate this UMRSS in our MSM cohort in Coastal Kenya, and compare it to a cohort-derived risk screening score (CDRSS) using our own data and similar methodology.

Since 2005, we have enrolled HIV-seronegative MSM in a cohort study of HIV-1 acquisition, as previously described [@R1]. Men made either monthly or quarterly scheduled visits at which risk reduction counseling was provided and a medical history and physical examination was performed. HIV-1 seroconversion was diagnosed using two rapid test kits (Determine, Abbott Laboratories, Abbott Park, Illinois, USA; Unigold, Trinity Biotech plc, Bray, Ireland) in parallel. Patients with discordant rapid HIV-1 test results were retested until discordancy was resolved. All seronegative and discordant samples were tested for p24 antigen (Vironostika HIV-1 p24 ELISA, Biomérieux, Ltd, Marcy l'Etoile, France). Up to 1 January 2012, preseroconversion and postseroconversion plasma samples were tested for HIV-1 RNA level (Amplicor Monitor, version 1.5; Roche, Branchburg, New Jersey, USA) with a positive result defined as more than 400 copies/ml [@R1]. All HIV diagnoses were confirmed by a positive RNA level (*n* = 67) or by follow-up until both rapid tests were positive (*n* = 6).

An AEHI visit was defined as a visit with an antibody seroconversion (determined by two positive rapid HIV tests), serodiscordant rapid HIV tests (one rapid test positive, one rapid test negative), or positive p24 antigen test. Eighteen (90%) of 20 patients with a positive p24 antigen test were clinically evaluated within 1 week of the test result [@R1].

HIV-1 incidence was estimated at 7.5% (95% confidence interval 6.0--9.5) per 100 person years during the study period. The median number of days from estimated date of HIV-1 infection to evaluation was 39 (interquartile range 19--59). At their AEHI visit, 42 patients had a rapid antibody seroconversion (after a documented seronegative result at the last study visit), 11 had a serodiscordant rapid HIV test, and 20 had a positive p24 antigen test. Characteristics reported (including symptoms experienced since the last study visit) at 73 AEHI visits were compared with characteristics reported at 6458 scheduled cohort visits ([Table 1](#T1){ref-type="table"}).

Cohort-derived risk screening score
===================================

To identify predictors of AEHI in our MSM cohort, we calculated unadjusted prevalence odds ratios for sociodemographic, medical history, and physical examination findings with AEHI as an outcome. We compared characteristics reported at AEHI visits to those reported at all seronegative visits, using generalized estimating equation (GEE) to adjust for intraindividual correlation. We constructed separate models for two specific domains (i.e. symptoms reported in past months and clinical examination findings), similar to the approach of Powers *et al.*[@R10]. Characteristics associated with AEHI at *P* ≤ 0.05 were included in initial multivariable models for two domains: 'symptom' and 'clinical examination' findings. We constructed a full, combined model including discordant rapid test results, age, fever, and the variables from the reduced, domain-specific models. Fever (or a history of having received treatment for unconfirmed 'malaria') was included *a priori* as this was the most significant reason for care seeking prior to seroconversion in our cohort [@R4]. The final model retained only predictors associated with AEHI at *P* ≤ 0.05 in the combined model. Data for men who seroconverted were censored at the AEHI visit.

Comparison of cohort-derived risk screening score with University of North Carolina-Malawi Risk Screening Score
===============================================================================================================

Similar to Powers' approach, we assigned each variable in the final cohort-derived model a predictor score equal to its β coefficient (natural log of the adjusted prevalence odds ratio) from the GEE model, rounded to the nearest integer ([Table 1](#T1){ref-type="table"}). Independent predictors for HIV-1 acquisition included in the CDRSS and their corresponding predictor scores were 1 for fever, fatigue, any symptomatic STD, diarrhea or age less than 30 years; and 4 for discordant HIV tests. The maximum score possible using the CDRSS was 9. Predictors in the UMRSS are shown in the last column of the [Table 1](#T1){ref-type="table"} and can sum to 11 [@R10]. We selected the CDRSS cut-off point that optimized sensitivity, specificity, and positive predictive values (details in the supplemental figure) and compared our results with UMRSS results. We calculated the AUC for the predictive ability of each score to identify a patient visit at which AEHI was diagnosed.

The UMRSS with a cut-off point at 2 had a sensitivity of 75.3%, specificity of 76.4%, and positive predictive value of 3.5% to identify AEHI correctly in our study population. Corresponding values for the CDRSS with a cut-off point at 2 were 80.8%, 76.0%, and 3.7%, respectively. The AUCs for the UMRSS and the CDRSS were 0.79 and 0.85, respectively (*P* \< 0.009). When we restricted the CDRSS to include only age less than 30 years, fever, or any symptomatic STD, the AUC became 0.77 (not different from the UMRSS).

To our knowledge, this is the first time that the UMRSS has been validated outside Malawi. Three of the six UMRSS characteristics (history of fever, diarrhea, and discordant rapid HIV tests) identified AEHI independently in our MSM population, and so were included in the CDRSS. The CDRSS had a better performance when all six predictors of AEHI in our cohort were included (additional characteristics: fatigue, age \<30 years, and symptomatic STD). Interestingly, a simplified CDRSS including only three characteristics (age \<30 years, fever, and any symptomatic STD) had a similar performance to the UMRSS.

Study limitations include possible ascertainment bias if patients overreported symptoms at their AEHI visit due to a seroconversion diagnosis, and the fact that we derived our validation from a very high-risk MSM population followed in a research setting. Although GUD was a predictor of AEHI in the study by Powers *et al*. [@R10], GUD was uncommon in this MSM population [@R1]. Fatigue was not a predictor of AEHI in STD patients in Malawi, but was frequently reported by our population and by men (but not women) in a large study of primary HIV-1 infection [@R11].

In summary, our study confirmed the importance of fever, diarrhea, and discordant HIV test results for the identification of AEHI in African populations, and demonstrated that targeted screening for AEHI in MSM could be performed using a CDRSS consisting of a limited set of characteristics, including age younger than 30 years, fever, diarrhea, fatigue, any symptomatic STD, and discordant HIV test results. Such screening for AEHI, when supported by risk reduction counseling and combination prevention therapy, will have substantial transmission prevention benefits [@R3].
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###### Comparison of clinical and behavior characteristics in MSM at acute and early HIV-1 infection and seronegative clinic visits, Coastal Kenya, 2005--2012.

  Predictor                                                 Acute or early HIV-1 infection visits (*n* = 73) *n* (%)   HIV-1 negative visits (*n* = 6458) *n* (%)   Unadjusted POR[^a^](#TF1-1){ref-type="table-fn"} (95% CI)   Domain-specific model adjusted POR (95% CI)[^b^](#TF1-2){ref-type="table-fn"}   Combined model adjusted POR (95% CI)[^c^](#TF1-3){ref-type="table-fn"}   Final model adjusted POR (95% CI)[^d^](#TF1-4){ref-type="table-fn"}   Cohort-derived Score[^e^](#TF1-5){ref-type="table-fn"}   UMRSS score[^f^](#TF1-6){ref-type="table-fn"}
  --------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------
  Sociobehavior and sociodemographic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   \>1 Sex partner in the past month                        46 (63.0)                                                  4677 (72.4)                                  0.8 (0.5--1.3)                                              0.6 (0.4--1.0)                                                                  --                                                                       --                                                                    --                                                       1
   Age \<30 years[^g^](#TF1-7){ref-type="table-fn"}         64 (87.7)                                                  4510 (69.8)                                  3.3 (1.6--6.8)                                              3.1 (1.5--6.2)                                                                  3.0 (1.3--6.9)                                                           3.3 (1.5--7.5)                                                        1                                                        --
  Symptoms reported in the past month or since last visit                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Fever[^h^](#TF1-8){ref-type="table-fn"}                  47 (64.4)                                                  1037 (16.1)                                  9.5 (5.8--15.7)                                             1.2 (0.6--2.5)                                                                  2.3 (1.2--4.6)                                                           2.8 (1.4--5.5)                                                        1                                                        1
   Joint or muscle pain                                     47 (64.4)                                                  1230 (19.1)                                  7.2 (4.4--11.9)                                             1.4 (0.7--2.8)                                                                  --                                                                       --                                                                    --                                                       1
   Head ache                                                45 (61.6)                                                  1244 (19.3)                                  6.7 (4.2--11.1)                                             1.4 (0.7--2.8)                                                                  --                                                                       --                                                                    --                                                       --
   Fatigue                                                  47 (64.4)                                                  939 (14.5)                                   10.9 (6.6--18.0)                                            2.2 (1.1--4.6)                                                                  3.8 (1.8--7.9)                                                           3.5 (1.8--6.8)                                                        1                                                        --
   Loss of appetite                                         39 (53.4)                                                  700 (10.8)                                   9.3 (5.8--15.0)                                             1.6 (0.9--2.9)                                                                  --                                                                       --                                                                    --                                                       --
   Night sweats                                             30 (41.1)                                                  449 (7.0)                                    9.7 (5.8 --16.2)                                            1.5 (0.8 --2.8)                                                                 --                                                                       --                                                                    --                                                       --
   Sore throat                                              26 (35.6)                                                  563 (8.7)                                    5.9 (3.5--9.8)                                              1.0 (0.5--2.0)                                                                  --                                                                       --                                                                    --                                                       --
   Diarrhea                                                 26 (35.6)                                                  411 (6.4)                                    8.6 (5.2--14.3)                                             2.1 (1.2--3.6)                                                                  2.7 (1.5--4.9)                                                           2.8 (1.6--4.9)                                                        1                                                        2
   Swollen glands                                           19 (26.0)                                                  328 (5.1)                                    6.6 (3.7--11.7)                                             1.2 (0.5--2.6)                                                                  --                                                                       --                                                                    --                                                       --
   Vomiting                                                 19 (26.0)                                                  290 (4.5)                                    6.9 (3.9--12.2)                                             1.1 (0.6--2.1)                                                                  --                                                                       --                                                                    --                                                       --
   Oral ulcers                                              14 (19.2)                                                  240 (3.7)                                    6.1 (3.2--11.5)                                             0.8 (0.4--1.6)                                                                  --                                                                       --                                                                    --                                                       --
   Too sick to work                                         33 (45.2)                                                  345 (5.3)                                    14.7 (8.9--24.5)                                            2.6 (1.4--4.7)                                                                  --                                                                       --                                                                                                                             
   Urethritis                                               8 (11.0)                                                   392 (6.1)                                    1.8 (0.8--3.9)                                              --                                                                              --                                                                       --                                                                    --                                                       --
   Proctitis                                                13 (17.8)                                                  273 (4.2)                                    6.5 (3.3--12.6)                                             --                                                                              --                                                                       --                                                                    --                                                       --
   Genital sores                                            10 (13.7)                                                  186 (2.9)                                    6.8 (3.2--14.2)                                             --                                                                              --                                                                       --                                                                    --                                                       --
   Any symptomatic STD                                      21 (28.8)                                                  614 (9.5)                                    4.2 (2.4--7.3)                                              1.7 (0.9--3.1)                                                                  2.0 (1.1--3.8)                                                           2.3 (1.3--4.0)                                                        1                                                        --
  Clinical examination at visit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Maculopapular rash                                       4 (6.0)                                                    100 (1.6)                                    4.1 (1.4--11.8)                                             2.8 (1.0--7.7)                                                                  1.7 (0.5--6.0)                                                           --                                                                    --                                                       --
   Conjunctivitis                                           14 (19.2)                                                  349 (5.4)                                    4.2 (2.2--7.8)                                              3.1 (1.7--5.9)                                                                  1.0 (0.4--2.3)                                                           --                                                                    --                                                       --
   Genital ulcer                                            1 (1.5)                                                    40 (0.6)                                     2.6 (0.3--21.3)                                             1.4 (0.2--10.2)                                                                 --                                                                       --                                                                    --                                                       2
   Genital warts                                            0                                                          34 (0.6)                                     --                                                          --                                                                              --                                                                       --                                                                    --                                                       --
   Lymph nodes                                              19 (26.0)                                                  736 (11.4)                                   2.8 (1.6--4.8)                                              --                                                                              --                                                                       --                                                                    --                                                       --
   Cervical                                                 12 (17.7)                                                  277 (4.3)                                    5.0 (2.5--9.8)                                              2.3 (1.1--4.8)                                                                  1.3 (0.5--3.0)                                                           --                                                                    --                                                       --
   Axillar                                                  2 (3.0)                                                    40 (0.6)                                     5.3 (1.2--23.8)                                             3.5 (0.8--14.8)                                                                 --                                                                       --                                                                    --                                                       --
   Inguinal                                                 15 (22.4)                                                  556 (8.9)                                    3.1 (1.7--5.6)                                              1.8 (1.0--3.1)                                                                  1.1 (0.5--2.4)                                                           --                                                                    --                                                       --
  Discordant HIV test results                               11 (15.1)                                                  14 (0.22)                                    73.5 (11.7--462.3)                                          N/A                                                                             53.5 (11.1--258.1)                                                       45.9 (9.2--229.7)                                                     4                                                        4

AEHI, acute and early HIV-1 infection; 95% CI, 95% confidence interval; GEE, generalized estimating equation; POR, prevalence odds ratio; STD, sexually transmitted disease; UMRSS, University of North Carolina-Malawi Risk Screening Score.

^a^Prevalence odds ratio.

^b^Factors associated with AEHI at *P* ≤ 0.05 were included in initial multivariable models for two domains: 'symptom' and 'clinical exam' findings.

^c^Factors associated with AEHI at *P* ≤ 0.05 in the initial domain-specific models were included in a combined model, to which age and discordant HIV test results were added.

^d^All variables in final model associated with AEHI at *P* ≤ 0.05.

^e^Predictor score is equal to its β coefficient (natural log of the adjusted prevalence odds ratio) from the GEE model, rounded to the nearest integer.

^f^UMRSS derived from multivariable analysis of predictors of acute HIV infection [@R10].

^g^Age \<30 years. Younger age in MSM was associated with HIV-1 acquisition in unadjusted multivariable analysis in our cohort [@R1].

^h^Included patients who had a history of presumptive 'malaria' treatment.
